August 15, 2018 Source: FiercePharma 165
Xolair of Novartis and Roche has been declared as a breakthrough therapy for food allergies including eggs, milk and peanuts by the Food and Drugs Administration (FDA).
The prevalence of food allergies is increasing day by day and could be life-threatening. It affects around 8% of children and 4% of adults in the U.S. To date, there are no FDA-approved treatments.
Xolair was initially used to treat allergic asthma where it met various rivals such as Teva’s Cinqair, GlaxoSmithKline’s Nucala, and AstraZeneca’s Fasenra, all with FDA approval to treat severe eosinophilic asthma.
Till now these drugmakers have been working continuously to include additional indications for their medicines, but none were working on food allergies. However, Sanofi was testing its novel Regeneron-partnered atopic dermatitis drug named Dupixent in order to treat peanut allergies.
Xolair received FDA approval recently for the treatment of chronic idiopathic urticaria, otherwise termed as chronic hives. This positive news helped the drug reprobate in $1.75 billion in the U.S. on last year.By Ddu
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.